Boehringer Ingelheim

For Healthcare Professionals

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Area

Section Overview

Metabolic

Oncology

Respiratory

Inflammation
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See all products

Products

See all products
Resources
Contact
Logout

Boehringer Ingelheim

All Specialties
Cardiology
Nephrology
Endocrinology
Primary Care
Prescribing Information

Shorts

Home
List of Products HCPs
Primary Care
Shorts

Toolbelt video Clinical relationship between heart and kidneys Angermann and Carvalho

Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)

Clinical relationship between the heart and the kidneys

Watch now Opens in new tab

Why is empagliflozin your first option to initiate in HF_Subodh Verma

Subodh Verma (Canada)

Why should empagliflozin be your first choice in heart failure management?

Watch now Opens in new tab

uti-gti

Lee-Ling Lim (Malaysia)

Expert opinion on reducing the risk of genital infections and UTIs when initiating SGLT2 inhibitors

Watch now Opens in new tab

Reducing the risk of diabetic ketoacidosis when initiating SGLT2 inhibitors

Lee-Ling Lim (Malaysia)

Reducing the risk of diabetic ketoacidosis when initiating SGLT2 inhibitors

Watch now Opens in new tab

Why is organ protection crucial in patients with cardiorenal metabolic conditions

Lee-Ling Lim (Malaysia)

Why is organ protection crucial in patients with cardiorenal metabolic conditions?

Watch now Opens in new tab

Practical tips animation video elderly frailty

Practical tips on initiating SGLT2 inhibitors in elderly/frail patients

Watch now Opens in new tab

Benefits of starting an SGLT2i upon clinical diagnosis of HF_Subodh Verma

Subodh Verma (Canada)

Benefits of starting an SGLT2 inhibitor upon clinical diagnosis of heart failure

Watch now Opens in new tab

Prof.Paweena Susantitaphong

Paweena Susantitaphong (Thailand)

Expert opinion on the eGFR dip when initiating SGLT2 inhibitors

Watch now Opens in new tab

Subodh Verma (Canada) | Soo Yong Lee (Korea)

SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 2)

Watch now Opens in new tab

Subodh Verma (Canada) | Soo Yong Lee (Korea)

SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 1)

Watch now Opens in new tab

Is the initial eGFR dip a concern_Angermann and Carvalho

Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)

Is the initial eGFR dip a cause for concern?

Watch now Opens in new tab

Let's Talk

Andrew Coats (Australia)

What is the impact of SGLT2 inhibitor trials in HFpEF?

Watch now Opens in new tab

Quick links

Quick Links

Shorts
Upcoming Events
Past Events
Resources
Patient Materials

Sitemap

Therapeutic Area

Resources

BI logo

Privacy
Terms of use
Sitemap
Contact

This website is intended for healthcare professionals in Singapore. The contents of this website are for information purposes only and are not intended to substitute for advice, treatment or recommendations of a healthcare professional. For your health concerns and other questions about symptoms, treatment or medication, consult a healthcare professional.

Copyright © 2025 Boehringer Ingelheim Singapore Pte. Ltd.
All rights reserved. Use of this Site is subject to the Terms of Use and Privacy Statement.